Introduction
============

Cancer is the main disease lead to death in the world. Approximately 14.1 million cancer cases occurred and 8.2 million cancer patients died in 2012[@B1]. Gastric cancer is the fourth most common cancer worldwide. It is also the second leading cause of cancer death. Every year, there are more than 950000 new gastric cancer patients [@B2]. Cancer is a complex disease. Endogenous factors (genetic, immune and endocrine disorders) and exogenous factors (unhealthy behaviors and environmental carcinogens) are both contributed to the cause of cancer [@B3]. However, under similar environmental circumstances, some people have cancers while others not may suggest genetic predisposition is vital in cancer development.

Single nucleotide polymorphisms (SNPs) are signal-base pairs in genomic DNA that vary in at least 1% of the population [@B4] and account for much of normal human genetic variation [@B5]. SNPs which have relationship with cancer are involved in lots of cellular pathways related to DNA repair, cell proliferation, apoptosis, chemotherapy targets and immune response [@B6]. Recently, genome-wide association study (GWAS) was used to identify the potential candidates for SNPs. Abnet et al.conducted a GWAS on Chinese population in 2010 and discovered MUC1 rs4072037 polymorphism was associated with the gastric cancer risk [@B7]. In 2011, Saeki et al. also found MUC1 rs4072037 polymorphism was associated with gastric cancer by the Japanese GC GWAS [@B8]. MUC1, or CA15.3, is expressed in epithelial linings in a different of tissues and is strongly expressed in the female genital tract during mammary gland and pregnancy and lactation [@B9]. Rs4072037, a functional SNP in exon 2 of the MUC1 gene, regulates splicing site selection during the posttranscriptional regulation process [@B10]. Besides gastric cancer, the MUC1 was also reported have association with colorectal cancer [@B11], ovarian cancer [@B12] and breast cancer [@B13]. But the consequences of these reports were controversial, we conducted this meta-analysis to evaluate a more precise association between the MUC1 rs4072037 polymorphism and cancer risk.

Materials and methods
=====================

Identification of Study
-----------------------

We searched Pubmed, Web of science and Cochrane library for relavant studies (updated to December, 2017). The search terms were \" \"Polymorphism, Single Nucleotide\" or \"Nucleotide Polymorphism, Single\" or \"Nucleotide Polymorphisms, Single\" or \"Polymorphisms, Single Nucleotide\" or \"Single Nucleotide Polymorphisms\" or \"SNPs\" or \"Single Nucleotide Polymorphism\" \" and \" \"Neoplasms\" or \"Neoplasia\" or \"Neoplasias\" or \"Neoplasm\" or \"Tumors\" or \"Tumor\" or \"Cancer\" or \"Cancers\" or \"Malignant Neoplasms\" or \"Malignant Neoplasm\" or \"Neoplasm, Malignant\" or \"Neoplasms, Malignant\" or \"Malignancy\" or \"Malignancies\" or \"Benign Neoplasms\" or \"Neoplasms, Benign\" or \"Benign Neoplasm\" or \"Neoplasm, Benign\" \" and \" \"MUC1\" or \"mucin1\" or \"1q22\" \", with no language limited. In addition, in order to identify additional relevant studies, references of retrieved articles were also included in the manual review.

Criteria of selection
---------------------

We selected studies according to these criteria: a. concerning the association between MUC1 rs4072037 and cancer risk. b. case-controls and cohort studies. c. identification of cancer was confirmed histologically. d. the number of each MUC1 rs4072037 genotype. e. genotype spreading of control compliance with Hardy-Weinberg equilibrium (HWE). When the same researcher had two or more publications covering the same patient population, the largest number study was included. There are major reasons for excluded the studies: a. case only studies. b. review papers, case report. c. HWE of controls was \< 0.05. d. not providing available genotype frequency. e. containing the data which have common characteristics.

Data extraction
---------------

The data of the studies was extracted by JX Feng and LY Liu independently. We extracted these information from studies: name of the first author, publication year, country of origin, ethnicity of cases and controls, type of study, type of cancer, genotyping method, source of controls, HWE of controls, number of cases and controls, frequencies of different genotypes (AA, AG and GG genotypes).

Quality assessment
------------------

According to the Newcastle-Ottawa Scale (NOS), FJX and LLY conducted quality assessment independently. When disagreement appeared, authors discussed to solve it. The score of study lower than 6 was considered as "low quality", otherwise was "high quality".

Statistical analysis
--------------------

To evaluate the strength of association between MUC1 rs4072037 polymorphism and cancer risk, crude odds ratios (ORs) and 95% confidence intervals (CIs) were used. The *Z* test was used to identify the statistical significance of pooled ORs. We calculated the pooled odds ratios (ORs) for the allelic model (G allele *vs*. A allele), heterozygote model (GA *vs*. AA), homozygote model (GG *vs*. AA), dominant model (GG+AG *vs*. AA) and recessive model (GG *vs*. AA+AG), respectively. To test the heterogeneity among studies, we performed a Cochrane chi-square-bsaed Q-test. In order to evaluate the statistical, I^2^ tests were used. To evaluate heterogeneity between studies, the I^2^ index which expresses the percentage of the total variation across studies due to heterogeneity was calculated. I^2^ values of 25%, 50% and 75% represents the low, median and high heterogeneity respectively. When I^2^ \>50%, the random effects (Dersimonian-Laird method) [@B14] was implemented to calculate overall OR value. Otherwise, I^2^ ≤50%, the fixed effects model (Mantel-Haenszel method) [@B15] was implemented. To search the heterogeneity between studies, subgroup analyses based on civilization, country, type of cancer, genotyping method and sample size were performed. Begg\'s funnel plot and Egger\'s linear regression test [@B16] were used to evaluate publication bias. We conducted sensitivity analyses by removing each single dataset to explore the influence of the single dataset on the pooled ORs. We used Stata software (version 12.0, Stata Corp, College Station, USA) to perform statistical analysis. All *P* values were two-sides and *P* ≤0.05 were considered statistically significant.

Consequences
============

Studying features
-----------------

The process of literature selection is shown in the **Figure [1](#F1){ref-type="fig"}**. A total 126 articles identified through database searching. After screening title, abstract or the whole text, 19 studies were evaluated for suitability. Then 2 studies were excepted due to genotype distributions of control inconsistent with HWE[@B17],[@B18]. Finally, 17 studies (19 datasets) with 12551 cases and 13436 controls were involved in this meta-analysis[@B8],[@B11]-[@B13],[@B19]-[@B31]. These studies were all case-control designed. There were 13 gastric cancer studies, 2 colorectal cancer studies, 1 breast cancer study, 1 lung cancer study, 1 ovarian cancer study and 1 esophagus cancer study. There were 13 studies of Asian descendent, 6 studies of Caucasian descendent and 1 study of American descendent. There were 10 studies used the genotyping method of TaqMan, 2 used the MassARRAY, 1 used the PCR-SSPs, 1 used the SNPlex and 1 used the KASP. The other characteristic of the studies were shown in the **Table [1](#T1){ref-type="table"}**.

Conclusions of Meta-analysis
----------------------------

The main consequences of this meta-analysis are shown in the **Table [2](#T2){ref-type="table"}.** MUC1 rs4072037 polymorphism is associated with significant decreased cancer risk in four genetic models (G *vs.* A: OR=0.79, 95%CI: 0.71-0.89, *P*\< 0.001 **Figure [2](#F2){ref-type="fig"}**; AG *vs.* AA: OR=0.72, 95%CI: 0.62-0.82, *P*\< 0.001 **Figure [3](#F3){ref-type="fig"}**; GG *vs.* AA: OR=0.78, 95%CI: 0.69-0.88, *P*\< 0.001 **Figure [4](#F4){ref-type="fig"}**; AG+GG *vs.* AA: OR=0.72, 95%CI: 0.63-0.83, *P*\< 0.001 **Figure [5](#F5){ref-type="fig"}**).

The subgroup analysis results were shown in the **Table [3](#T3){ref-type="table"}**. By subgroup analysis in ethnicity, a reduced risk of cancer was found in entire genetic models (G *vs.* A: OR=0.75, 95%CI: 0.65-0.87, *P*\< 0.001; AG *vs.* AA: OR=0.72, 95%CI: 0.61-0.85, *P*\< 0.001; GG *vs.* AA: OR=0.75, 95%CI: 0.64-0.89, *P*= 0.001; AG+GG *vs.* AA: OR=0.72, 95%CI: 0.61-0.85, *P*\< 0.001; GG *vs.* AG+AA, OR=0.81, 95%CI: 0.69-0.96, *P*= 0.013) among Asian descendent. However no similar association was found among Caucasian descendent. Furthermore, significantly reduced gastric cancer risk was found in entire genetic models (G *vs.* A: OR=0.70, 95%CI: 0.63-0.78, *P*\< 0.001; AG *vs.* AA: OR=0.64, 95%CI: 0.55-0.74, *P*\< 0.001; GG *vs.* AA: OR=0.62, 95%CI: 0.53-0.73, *P*\< 0.001; AG+GG *vs.* AA: OR=0.64, 95%CI: 0.55-0.73, *P*\< 0.001; GG *vs.* AG+AA, OR=0.75, 95%CI: 0.64-0.87, *P*\< 0.001). However, no similar association was discovered in colorectal cancer and other cancers (breast cancer, lung cancer, ovarian cancer and esophagus cancer). Stratification by country (China and Japan), genotyping methods (TaqMan and other methods) or sample size (\<1000 and ≥ 1000 subjects) all showed MUC1 rs4072037 polymorphism associated with an decreased cancer risk in all genetic models except recessive model.

Sensitivity analysis
--------------------

To reflect the effect of single study on the pooled ORs, we conducted sensitivity analysis by excising each study. Because the corresponding pooled ORs did not materially altered, the meta results were statistically robust (**Figure [6](#F6){ref-type="fig"}**).

Publication bias
----------------

To determine the publication bias of studies, Begg\'s funnel plot and Egger\'s test were implemented. The results showed that the figure of the funnel was meristic under the dominant model **(Figure [7](#F7){ref-type="fig"})**. In addition, the results of Egger\'s test quantitatively convinced there was no publication bias in these studies (**Table [4](#T4){ref-type="table"}**).

Discussion
==========

Meta-analysis is a crucial statistical technique which has more statistical power than a single study. It can quantitatively combine analyses from different studies. Because of the association between cancer risk and MUC1 rs4072037 polymorphism are conflicted, we performed this meta-analysis to solve the problem. In our meta-analysis, we found the G allele locus on rs4072037 was associated with significantly decreased cancer risk. Subgroup analysis by cancer type indicated that G allele was associated with decreased gastric cancer risk, but not colorectal cancer or other cancers (breast cancer, lung cancer, ovarian cancer and esophagus cancer). We performed subgroup analysis by ethnicity and found G allele was associated with decreased cancer risk among Asian but not Caucasian. The consequences was not changed when stratification by country, genotyping methods or sample size. The MUC1 gene is used to encode membrane-bound glycosylated phosphorprotein and it is a member of the mucin family. There were several studies focus on the relationship between MUC1 rs4072037 polymorphism and the risk of cancer. However, Zheng et al. [@B32] Giraldi et al.[@B33] and Liu et al. [@B34] included fewer studies and only focused on the relationship of the gastric cancer and MUC1 rs4072037 polymorphism. Duan et al.[@B35] covered only 3 types of cancer, including 8 researches on cancer of stomach and one each on breast cancer and colorectal cancer. Comparing with these meta-analyses, our meta-analysis has involved more studies, which 12551 cases and 13436 controls were involved. In addition, the result of Duan et al showed MUC1 rs4072037 polymorphism was associated with decreased cancer risk in recessive model, but the result of our meta-analysis showed they have no association (OR=0.90, 95%CI: 0.81-1.01, *P=*0.07). In the subgroup analysis, Duan et al found a decreased association between MUC1 rs4072037 polymorphism and cancer risk in allelic model, heterozygote model and dominant model among Caucasian. However, the result of our meta-analysis showed they have no association among Caucasian under all genetic model.

When we interpreted the results of meta-analyses, there was possibly heterogeneity. It is an important goal to discover the provenience of heterogeneity in meta-analysis [@B36]. To assess the heterogeneity, the I^2^ statistic was used. We found the results of our meta-analysis showed significant heterogeneity in allelic, co-dominant and dominant models. To discover the provenience of heterogeneity, we performed subgroup analysis, meta regression and sensitivity analysis. In the subgroup analysis, we discovered type of cancer may be a source of heterogeneity. Then we conducted sensitivity analysis in GC group. When we took out the Song et al [@B30] and Zhang B et al [@B23], the I^2^ statistic was significantly decreased (**Table [5](#T5){ref-type="table"}**).

There were still some limits in our meta-analysis. Firstly, publication bias might exist because we just included published studies. Secondly, we knew diet, smoking and other environmental risk might be factors for cancer. However, because of limited information, we cannot explore the associations between these factors and cancers. Last but not least, the heterogeneity of our meta-analysis in some models is high. Though we found the source of heterogeneity, we thought there might be others.

In summary, our meta-analysis found MUC1 rs4072037 polymorphism was associated with lower cancer risk, particularly in gastric cancer and Asians. It might be used as a tumor marker.
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![Begg\'s funnel plot of MUC1 rs4072037 polymorphism and cancer risk for homozygous genetic model (GG *vs*. AA)](jcav09p3343g007){#F7}

###### 

Characteristics of included studies

  Study              Year   Country      Ethnicity   Study-type     Cancer-type   Genotyping method   Source of control   Case   Control   *P*~HWE~   NOS
  ------------------ ------ ------------ ----------- -------------- ------------- ------------------- ------------------- ------ --------- ---------- -----
  Song[@B30]         2013   Korea        Asian       Case-control   GC            TaqMan              Population          3225   1697      0.279      6
  Zhang H[@B24]      2011   China        Asian       Case-control   GC            TaqMan              Population          1658   1833      0.335      8
  Kruit[@B13]        2009   Netherland   European    Case-control   BC            TaqMan              Population          229    208       0.985      6
  Li F[@B19]         2012   China        Asian       Case-control   CRC           MassARRAY           Population          230    291       0.434      8
  Kupcinskas[@B20]   2014   Lithuania    European    Case-control   GC            TaqMan              Population          249    232       0.284      6
  Horimasu[@B21]     2017   Japan        Asian       Case-control   LC            TaqMan              Population          172    276       0.773      7
  Yang[@B22]         2012   China        Asian       Case-control   GC            MassARRAY           Population          249    100       0.223      7
  Zhang B[@B23]      2013   China        Asian       Case-control   GC            PCR-SSPs            Population          283    281       0.992      8
  Kupcinskas[@B11]   2015   Lithuania    European    Case-control   CRC           TaqMan              Population          192    362       0.64       6
  Palmer[@B17]^a^    2013   Poland       European    Case-control   EC            TaqMan              Population          159    207       0.024      6
  Palmer[@B17]^a^    2013   Poland       European    Case-control   GC            TaqMan              Population          311    207       0.024      6
  Cai[@B25]          2017   China        Asian       Case-control   GC            KASP                Population          480    488       0.975      6
  Dai[@B26]          2014   China        Asian       Case-control   EC            TaqMan              Population          2072   2204      0.808      7
  Jia[@B27]          2011   Poland       European    Case-control   GC            SNPlex              Population          272    376       0.483      7
  Li M[@B28]         2013   China        Asian       Case-control   GC            TaqMan              Population          335    334       0.242      7
  Williams[@B12]     2014   America      America     Case-control   OC            TaqMan              Population          727    757       0.939      6
  Sun H[@B29]        2015   China        Asian       Case-control   GC            TaqMan              Hospital            692    774       0.735      7
  Sun Y[@B31]        2014   America      European    Case-control   GC            TaqMan              Population          129    123       0.872      7
  Qiu[@B18]^a^       2016   China        Asian       Case-control   GC            TaqMan              Hospital            1124   1192      \<0.001    7
  Saeki-T[@B8]       2011   Japan        Asian       Case-control   GC            TaqMan              Population          605    1264      0.466      8
  Saeki-A[@B8]       2011   Japan        Asian       Case-control   GC            TaqMan              Population          303    1467      0.11       8
  Saeki-K[@B8]       2011   Korea        Asian       Case-control   GC            TaqMan              Population          449    369       0.391      8

^a^: Studies did not follow the HWE

GC: gastric cancer; BC: breast cancer; CRC: colorectal cancer; LC: lung cancer; EG: esophagus cancer; OC: ovarian cancer

T: Tokyo; A: Aichi; K: Korea

NOS: Newcastle-Ottawa Scale

###### 

Main results of meta-analysis

  Comparisons   Heterogeneity test   Summary OR (95% CI)   Hypothesis test   Datasets                        
  ------------- -------------------- --------------------- ----------------- ----------------- ------ ------ ----
  G vs A        93.38                0                     80.7              0.79(0.71,0.89)   4.07   0      19
  AG vs AA      84.59                0                     78.7              0.72(0.62,0.82)   4.65   0      19
  GG vs AA      35.33                0.009                 49.1              0.78(0.69,0.88)   4.02   0      19
  AG+GG vs AA   94.37                0                     80.9              0.72(0.63,0.83)   4.5    0      19
  GG vs AG+AA   21.54                0.253                 16.4              0.90(0.81,1.01)   1.81   0.07   19

###### 

Subgroup analysis of meta-analysis

  Comparisons         Heterogeneity test   Summary OR (95% CI)   Hypothesis test   Datasets                         
  ------------------- -------------------- --------------------- ----------------- ----------------- ------ ------- ----
  Ethnic                                                                                                            
  Asian                                                                                                             
  G vs A              68.54                0                     82.5              0.75(0.65,0.87)   3.92   0       13
  AG vs AA            67.31                0                     82.2              0.72(0.61,0.85)   3.9    0       13
  GG vs AA            13.41                0.34                  10.5              0.75(0.64,0.89)   3.31   0.001   13
  AG+GG vs AA         71.96                0                     83.3              0.72(0.61,0.85)   3.94   0       13
  GG vs AG+AA         9.72                 0.64                  0                 0.81(0.69,0.96)   2.48   0.013   13
  Caucasian                                                                                                         
  G vs A              18.78                0.001                 78.7              0.85(0.66,1.10)   1.24   0.215   5
  AG vs AA            15.24                0.004                 73.7              0.68(0.47,1.01)   1.92   0.054   5
  GG vs AA            18.95                0.001                 78.9              0.74(0.44,1.24)   1.14   0.255   5
  AG+GG vs AA         20                   0.001                 80                0.70(0.47,1.07)   1.65   0.098   5
  GG vs AG+AA         8                    0.091                 50                0.92(0.76,1.12)   0.82   0.412   5
  Cancer type                                                                                                       
  Gastric cancer                                                                                                    
  G vs A              33.71                0.001                 64.4              0.70(0.63,0.78)   6.39   0       13
  AG vs AA            37.33                0                     67.9              0.64(0.55,0.74)   6.19   0       13
  GG vs AA            15.47                0.217                 22.4              0.62(0.53,0.73)   5.76   0       13
  AG+GG vs AA         41.29                0                     70.9              0.64(0.55,0.73)   6.2    0       13
  GG vs AG+AA         7.81                 0.8                   0                 0.75(0.64,0.87)   3.68   0       13
  Colorectal cancer                                                                                                 
  G vs A              4.39                 0.036                 77.2              0.97(0.63,1.47)   0.17   0.867   2
  AG vs AA            2.67                 0.102                 62.6              0.94(0.59,1.50)   0.26   0.794   2
  GG vs AA            2.02                 0.155                 50.6              1.07(0.54,2.12)   0.19   0.846   2
  AG+GG vs AA         3.74                 0.053                 73.2              0.96(0.57,1.62)   0.16   0.874   2
  GG vs AG+AA         1.12                 0.29                  10.8              1.12(0.77,1.63)   0.61   0.542   2
  Other cancers                                                                                                     
  G vs A              1.46                 0.691                 0                 1.04(0.96,1.13)   0.91   0.364   4
  AG vs AA            6.37                 0.095                 52.9              0.95(0.78,1.16)   0.53   0.599   4
  GG vs AA            0.51                 0.917                 0                 1.03(0.84,1.26)   0.24   0.809   4
  AG+GG vs AA         4.13                 0.248                 27.3              1.03(0.92,1.14)   0.48   0.631   4
  GG vs AG+AA         0.97                 0.808                 0                 1.12(0.93,1.34)   1.18   0.24    4
  Country                                                                                                           
  China                                                                                                             
  G vs A              44.47                0                     84.3              0.80(0.66,0.96)   2.34   0.019   8
  AG vs AA            42.9                 0                     83.5              0.76(0.61,0.95)   2.38   0.018   8
  GG vs AA            10.93                0.142                 36                0.80(0.65,0.98)   2.14   0.032   8
  AG+GG vs AA         46.14                0                     84.8              0.76(0.61,0.95)   2.38   0.018   8
  GG vs AG+AA         8.27                 0.31                  15.3              0.85(0.69,1.04)   1.57   0.117   8
  Japan                                                                                                             
  G vs A              6.29                 0.043                 68.2              0.68(0.52,0.91)   2.66   0.008   3
  AG vs AA            7.4                  0.025                 73                0.65(0.45,0.93)   2.37   0.018   3
  GG vs AA            0.26                 0.877                 0                 0.60(0.39,0.94)   2.26   0.024   3
  AG+GG vs AA         7.14                 0.028                 72                0.65(0.46,0.91)   2.53   0.011   3
  GG vs AG+AA         0.1                  0.95                  0                 0.68(0.44,1.06)   1.72   0.085   3
  Other countries                                                                                                   
  G vs A              32.41                0                     78.4              0.82(0.70,0.97)   2.29   0.022   8
  AG vs AA            26.11                0                     73.2              0.70(0.56,0.87)   3.15   0.002   8
  GG vs AA            22.63                0.002                 69.1              0.76(0.56,1.04)   1.69   0.091   8
  AG+GG vs AA         31.78                0                     78                0.71(0.56,0.90)   2.86   0.004   8
  GG vs AG+AA         10.66                0.154                 34.3              0.96(0.83,1.10)   0.59   0.552   8
  Genotyping method                                                                                                 
  TaqMan                                                                                                            
  G vs A              82                   0                     84.1              0.79(0.69,0.91)   3.37   0.001   14
  AG vs AA            70.34                0                     81.5              0.72(0.61,0.85)   3.97   0       14
  GG vs AA            28.35                0.008                 54.1              0.78(0.63,0.97)   2.27   0.023   14
  AG+GG vs AA         79.16                0                     83.6              0.73(0.62,0.86)   3.8    0       14
  GG vs AG+AA         18.87                0.127                 31.1              0.93(0.82,1.05)   1.19   0.233   14
  Other methods                                                                                                     
  G vs A              8.4                  0.078                 52.4              0.77(0.64,0.93)   2.73   0.006   5
  AG vs AA            11.64                0.02                  65.6              0.71(0.53,0.95)   2.34   0.019   5
  GG vs AA            4.47                 0.346                 10.5              0.63(0.46,0.85)   3.04   0.002   5
  AG+GG vs AA         12.33                0.015                 67.6              0.71(0.53,0.94)   2.38   0.017   5
  GG vs AG+AA         1.32                 0.857                 0                 0.78(0.59,1.03)   1.77   0.077   5
  Sample size                                                                                                       
  \<1000                                                                                                            
  G vs A              42.21                0                     73.9              0.78(0.66,0.92)   2.92   0.004   12
  AG vs AA            34.14                0                     67.8              0.70(0.57,0.85)   3.48   0.001   12
  GG vs AA            24.33                0.011                 54.8              0.71(0.52,0.96)   2.23   0.026   12
  AG+GG vs AA         39.97                0                     72.5              0.70(0.57,0.87)   3.29   0.001   12
  GG vs AG+AA         13.57                0.258                 18.9              0.87(0.74,1.03)   1.61   0.107   12
  ≥1000                                                                                                             
  G vs A              47.49                0                     87.4              0.80(0.68,0.95)   2.62   0.009   7
  AG vs AA            43.27                0                     86.1              0.75(0.61,0.91)   2.93   0.003   7
  GG vs AA            8.96                 0.176                 33.1              0.84(0.72,0.99)   2.14   0.032   7
  AG+GG vs AA         46.84                0                     87.2              0.76(0.62,0.92)   2.83   0.005   7
  GG vs AG+AA         7.72                 0.26                  22.2              0.93(0.80,1.08)   0.99   0.323   7

###### 

Publication bias of meta-analysis for Egger\'s test

  Model         T-value   *P*-value   95% CI of intercept value
  ------------- --------- ----------- ---------------------------
  G vs A        -1.33     0.202       (-4.614735,1.053355)
  AG vs AA      -1.63     0.121       (-4.139911,0.5275983)
  GG vs AA      -0.97     0.345       (-2.638502,0.9741915)
  AG+GG vs AA   -1.47     0.159       (-4.310014,0.7678419)
  GG vs AG+AA   -1.52     0.147       (-2.141581,0.3494686)

###### 

The main result of removing Song et al and Zhang B et al.

  Comparisons   Heterogeneity test   Summary OR (95% CI)   Hypothesis test   Datasets                      
  ------------- -------------------- --------------------- ----------------- ----------------- ------- --- ----
  G vs A        18.04                0.054                 44.6              0.67(0.63,0.72)   11.37   0   11
  AG vs AA      18.31                0.05                  45.4              0.61(0.56,0.66)   11.29   0   11
  GG vs AA      12.28                0.267                 18.6              0.58(0.48,0.69)   5.91    0   11
  AG+GG vs AA   21.05                0.021                 52.5              0.59(0.52,0.67)   7.81    0   11
  GG vs AG+AA   7.03                 0.723                 0                 0.73(0.62,0.86)   3.69    0   11
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